New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:42 EDTAMAGAMAG sees FY13 revenue $73M- $77M, consensus $79.12M
AMAG sees Feraheme U.S. net product revenues of between $63M-$67M, driven by a combination of price and double-digit volume growth; Royalties and product sales related to ex-U.S. sales of Feraheme/Rienso and recognition of milestones of approximately $10M.
News For AMAG From The Last 14 Days
Check below for free stories on AMAG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:20 EDTAMAGAMAG Pharmaceuticals raises FY14 revenue view to $93M-$102M, consensus $93.78M
AMAG Pharmaceuticals sees U.S. Feraheme net product sales of $80M-$87M, revised upward from the company's previous estimate of $75M-$85M; revenue from MuGard, ex-U.S. Feraheme product sales, royalties and milestones of $13M-$15M; lowered cost of goods sold guidance to 13%-15% of Feraheme net product sales from the company's previous estimate of 14%-16%; Increased total operating expense guidance to $87M-$92M from the company's previous estimate of $80M-$85M resulting from increased: Research and development expenses of $21M-$23M; Selling, general and administrative expenses of $66M-$69M; increased net loss guidance to $12M-$14M from the company's previous estimate of $10M-$12M. Both estimates include approximately $11M of interest expense from the $200M convertible debt offering in February 2014; lowered ending cash and investments guidance to $388M-$393M from the company's previous estimate of $392M-$397M at December 31.
07:15 EDTAMAGAMAG Pharmaceuticals reports Q2 EPS (7c), consensus (9c)
Reports Q2 revenue $24.8M, consensus $23.35M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use